Navigation Links
Cancer breakthrough to prevent heart failure and increase survival rates
Date:2/9/2011

A breakthrough by scientists at Queen's University Belfast could help reduce heart failure in cancer patients around the world, and ultimately increase survival rates.

Scientists at Queen's Centre for Vision and Vascular Science have discovered the role of an enzyme which, when a patient receives chemotherapy, can cause life-threatening damage to the heart. This has, until now, restricted the amount of chemotherapy doses a patient can receive; but while protecting the heart, this dilutes the chemotherapy's effectiveness in destroying cancerous tumours.

By identifying the role of the enzyme - NADPH oxidase - work can now go ahead into making chemotherapy treatments more effective and reduce the toxic effects of cancer treatment on the heart.

Dr David Grieve, jointly leading on the research at Queen's School of Medicine, Dentistry and Biomedical Sciences said: "While chemotherapy drugs are highly effective in treating a wide range of tumours, they can also cause irreversible damage to the heart. This means that doctors are restricted in the doses they can administer to patients. In recent years, scientists have been searching for new drugs to prevent these side-effects.

"Although we have known about the NADPH oxidase enzyme for many years, until now, we were not aware of its crucial role in causing heart damage associated with chemotherapy. Our research findings hold clear potential for the creation of new drugs to block the action of the enzyme, which could significantly reduce heart damage in cancer patients.

"Ultimately, this could allow for the safer use of higher doses of chemotherapy drugs and make the treatment more effective against tumours. Despite improved treatments, cancer is currently responsible for 25 per cent of all mortality in the western world. By reducing the risk of heart failure associated with chemotherapy, patient survival rates could be significantly increased."

Scientists at Queen's are now concentrating
'/>"/>

Contact: Anne-Marie Clarke
anne-marie.clarke@qub.ac.uk
44-028-909-75320
Queen's University Belfast
Source:Eurekalert

Page: 1 2

Related biology news :

1. Photodynamic therapy against cancer
2. Sweeping view of prostate cancer genome yields deep insights
3. Research team honored for innovative science to advance cancer research
4. Blood-clotting protein linked to cancer and septicemia
5. Discovery may lead to turning back the clock on ovarian cancer
6. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
7. Early tests find nanoshell therapy effective against brain cancer
8. Scientists synthesize long-sought-after anticancer agent
9. Cornell Dots that light up cancer cells go into clinical trials
10. Antibiotic offers potential for anti-cancer activity
11. Cancer drug aids the regeneration of spinal cord injuries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... Orlando, FL (May 18, 2013) An increasing ... that require interventions to resolve, according to research ... In one study targeting obesity, researchers at the ... have a unique pattern of exhaled breath compared ... in volatile organic compound levels that can be ...
(Date:5/17/2013)... of New Jersey, and City University of New York ... that effectively clears organisms to be viewed under ... hydrate, which is one of the few high-quality clearing ... the Drug Enforcement Administration (DEA) due to its use ... are vital for viewing organisms under a microscope. Without ...
(Date:5/17/2013)... 17, 2013, Shenzhen, China---- Why Tibetan antelope can ... Plateau? In a collaborative research published in ... and other institutes provide evidence that some genetic ... to harsh highland environments. The data in this ... genetic mechanisms and the biology of other ruminant ...
Breaking Biology News(10 mins):New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... 15, 2012 ChromaDex Corporation (OTCBB: CDXC) an ... solutions and ingredients to the dietary supplement, food ... financial results for the fiscal year ended December ... accordance with United States Generally Accepted Accounting Principles ...
... , , , , , , ... , , AUDIO: This ... , Click here for more information. , ... , , , , ...
... with conservation tillage increases, more growers are encountering slugs, ... virtually all crops, and they are challenging to control ... are available. In "Slug (Mollusca: Agriolimacidae, Arionidae) Ecology ... on the mid-Atlantic Region," a free, open-access article appearing ...
Cached Biology News:ChromaDex® Announces Financial Results for the Year Ended 2011 2ChromaDex® Announces Financial Results for the Year Ended 2011 3ChromaDex® Announces Financial Results for the Year Ended 2011 4ChromaDex® Announces Financial Results for the Year Ended 2011 5Common North American frog identified as carrier of deadly amphibian disease 2Common North American frog identified as carrier of deadly amphibian disease 3Common North American frog identified as carrier of deadly amphibian disease 4
(Date:5/16/2013)... 16, 2013 As the weather warms, women ... favorite Spring looks. While most make a statement with fashion, ... women find the warmer weather mixes makeup and sweat to ... the onset of acne during warmer months, Adult Acne ... treatment users the best ways to deter breakouts. , ...
(Date:5/16/2013)... , May 16, 2013 /PRNewswire/ ... market research report is available in ... Competitor Analysis: Therapeutic Proteins ... http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical   ...   The new Competitive ...
(Date:5/16/2013)... Arlington, VA (PRWEB) May 16, 2013 ... for Primary Cells & Stem Cell-Derived Cells: Current and ... low, the number of suppliers in the primary cells ... examines what cell types are used most often, how ... is the market size and anticipated growth rate. ...
(Date:5/16/2013)... Stephen Y. Chou, Founder of Nanonex Corporation, will be ... IEEE Nano 2013 in Beijing, China, on August 5th ... becoming one of the most critical nanofabrication technologies today ... large area, and low cost unmatchable by other nanofabrication ... a broad range of industries, from ICs, nano/micro optical ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013 2
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today ... month period ended March 31, 2008., "We ... total of nine,clinical trials, four exploring the use ... use of REOLYSIN(R) in combination with a variety ...
... Squibb,Company (NYSE: BMY ) invites investors and the ... meeting with stockholders at 10 a.m. ET on Tuesday,May ... items to be,transacted, senior executives will review the status ... listen to the webcast, please visit the,Investor Relations page ...
... Training Institute joins the SURGEX(TM) Team, ... Inc., wholly-owned subsidiary of Millennium Biotechnologies,Group, Inc. ... SURGEX(TM) has,become the official sports nutrition drink ... Florida,s premier basketball training facility for,NBA stars ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces 2008 First Quarter Results 2Oncolytics Biotech Inc. Announces 2008 First Quarter Results 3Oncolytics Biotech Inc. Announces 2008 First Quarter Results 4Oncolytics Biotech Inc. Announces 2008 First Quarter Results 5Oncolytics Biotech Inc. Announces 2008 First Quarter Results 6Oncolytics Biotech Inc. Announces 2008 First Quarter Results 7Oncolytics Biotech Inc. Announces 2008 First Quarter Results 8Oncolytics Biotech Inc. Announces 2008 First Quarter Results 9Oncolytics Biotech Inc. Announces 2008 First Quarter Results 10Oncolytics Biotech Inc. Announces 2008 First Quarter Results 11Oncolytics Biotech Inc. Announces 2008 First Quarter Results 12Oncolytics Biotech Inc. Announces 2008 First Quarter Results 13Oncolytics Biotech Inc. Announces 2008 First Quarter Results 14Oncolytics Biotech Inc. Announces 2008 First Quarter Results 15Oncolytics Biotech Inc. Announces 2008 First Quarter Results 16Oncolytics Biotech Inc. Announces 2008 First Quarter Results 17Oncolytics Biotech Inc. Announces 2008 First Quarter Results 18Oncolytics Biotech Inc. Announces 2008 First Quarter Results 19Oncolytics Biotech Inc. Announces 2008 First Quarter Results 20Oncolytics Biotech Inc. Announces 2008 First Quarter Results 21Oncolytics Biotech Inc. Announces 2008 First Quarter Results 22Oncolytics Biotech Inc. Announces 2008 First Quarter Results 23Oncolytics Biotech Inc. Announces 2008 First Quarter Results 24Oncolytics Biotech Inc. Announces 2008 First Quarter Results 25Oncolytics Biotech Inc. Announces 2008 First Quarter Results 26Oncolytics Biotech Inc. Announces 2008 First Quarter Results 27Oncolytics Biotech Inc. Announces 2008 First Quarter Results 28Oncolytics Biotech Inc. Announces 2008 First Quarter Results 29Oncolytics Biotech Inc. Announces 2008 First Quarter Results 30Oncolytics Biotech Inc. Announces 2008 First Quarter Results 31Oncolytics Biotech Inc. Announces 2008 First Quarter Results 32Oncolytics Biotech Inc. Announces 2008 First Quarter Results 33SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility 2SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility 3
... stored within neurons in vesicles called ... the synaptic bouton. Synaptosomes may ... from other cellular debris. Abnormalites in ... many pathological condtions. Conditions of ...
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,515-8) or ...
... of your microarray data using Asuragens ... you need from consultation to extensive ... to date methods. Utilize our expertise ... Profiling Service or from your own ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: ...
Biology Products: